The peptide Epitalon (Epithalon; AEDG, Ala-Glu-Asp-Gly) has been administered in published animal studies and laboratory experiments at very different times, with varying frequencies, and for different periods. However, no controlled human studies have established the best time of day, the superiority of morning versus evening administration, or a standardised clinical cycle. [1–8]
Questions like „when to use Epitalon”, „Epitalon in the morning or evening” and „how long should an Epitalon cycle last?” are often discussed online as if a single standard protocol existed. Published scientific literature does not support such a simplification.
Some studies used five consecutive days of administration each month, others administered Epitalon five times a week for several months, and still others involved short-term nasal exposure in rats. Studies with oral administration sometimes lasted a month. Studies of the circadian rhythm measured nocturnal melatonin concentration or evening hormonal responses, but the time of measurement should not be equated with evidence that Epitalon itself should be administered in the evening.
When was Epitalon administered in studies?
Epitalon has been administered according to many different research regimens, rather than at a single standard time. Animal studies have included, among others, five consecutive days of administration each month, five administrations per week for many months, single acute intranasal exposures, and monthly oral regimens. The schedule was chosen to suit the studied endpoint rather than based on a validated human treatment protocol. [1–6]
One of the most transparent examples comes from a long-term ageing study in mice. Swiss-derived SHR female mice were administered 1 μg of Epitalon subcutaneously for five consecutive days each month, starting from the third month of life until natural death. [1]
In another study on female CBA mice, a similar monthly schedule was used, but with a lower experimental amount: 0.1 μg per animal for five consecutive days each month, starting from the sixth month of life until natural death. [2]
Other studies did not use monthly cycles. In one long-term mouse carcinogenicity study, Epitalon was administered by injection five times a week for 6.5 months. [3]
In turn, in a study on rats, Epithalon was administered orally for one month, analysing the activity of small intestine enzymes. [4]
In a neurophysiological study on rats, a single intranasal administration was used, followed by the rapid recording of cortical neuronal activity, rather than a prolonged administration regimen. [5]
These examples show that the timing and regimen of Epitalon administration depended on the specific research question.
Epitalon in the morning or in the evening?
Published studies have not shown that Epitalon should be administered specifically in the morning or in the evening. Although several studies have measured evening or night-time melatonin concentrations due to Epitalon’s association with pineal gland function and the circadian rhythm, taking measurements during the biological night does not constitute evidence of the superiority of evening administration. [6–8]
The question of whether to use it in the morning or in the evening largely stems from research on melatonin.
Melatonin naturally follows a circadian rhythm, with its concentration increasing during the biological night. Therefore, researchers analysing the potential impact of Epitalon on age-related changes in pineal gland function often measured melatonin in the evening or at night.
For example, in a study on primates, Epitalon significantly stimulated evening melatonin synthesis in ageing rhesus macaques and was associated with the normalisation of the circadian rhythm of cortisol. [6]
Another study on rhesus macaques found lower nocturnal melatonin concentrations in older animals and analysed whether Epitalon could affect age-related hormonal disorders. [7]
A separate publication involving old monkeys and elderly humans described the restoration of nocturnal levels of endogenous melatonin and the normalisation of its circadian rhythm following the administration of pineal peptides. [8]
However, none of these results establish a clinical rule according to which Epitalon should be administered before sleep.
Above all, they show that night-time is an important measurement period in research into hormones associated with the circadian rhythm.
According to published research, what is the best time of day?
No best time of day for using Epitalon has been established. In the published literature, there is no controlled human study directly comparing morning and evening administration and demonstrating superior efficacy, absorption, safety, impact on sleep, melatonin response, or longevity-related effects at either of those times.
An evidence-based answer to the question „what is the best time of day to use Epitalon?” would require a study directly comparing administration at different times of the day.
For example, researchers could compare morning versus evening administration while keeping the same dose, route of administration, duration, study population, and experimental conditions. Pharmacokinetics, melatonin, circadian phase, sleep, adverse events, or another pre-specified endpoint could then be evaluated.
The available literature regarding Epitalon does not contain such a study.
This distinction is important because chronobiology can make the time of administration biologically relevant without indicating specifically which time is the correct one.
Melatonin itself is highly time-dependent. In other experimental contexts, the biological response to melatonin may vary depending on the phase of the circadian rhythm. However, this general principle of chronobiology does not mean that Epitalon has the same profile of dependence on the time of administration.
Therefore, recommending the use of Epitalon in the morning or evening based solely on studies concerning melatonin would be going beyond the available evidence.
How long did the Epitalon cycles last in the studies?
Epitalon research cycles ranged from single acute exposure, through repeated five-day monthly cycles and monthly studies with oral administration, to multi-month repeated administration and regimens covering a significant portion of the animal's life. There is no single published cycle length that has been validated as an optimal regimen for humans. [1–5]
The duration largely depended on what the researchers intended to measure.
Five-day monthly cycles
A few classic studies on ageing and cancer used five consecutive days of administration each month.
In an experiment on longevity in SHR mice, the five-day monthly cycle was initiated in the third month of life and continued until natural death. [1]
In the study on CBA mice, the same five-day monthly regimen was used, starting in the sixth month of life. [2]
In the experiment on HER-2/neu transgenic mice, Epithalon was also administered for five consecutive days each month, starting from the second month of life. [9]
Five times a week for many months
Other studies have used a more continuous design.
In one long-term experiment on C3H/He mice, Epitalon was administered five times a week for 6.5 months. [3]
Monthly oral administration
Elderly Wistar rats were given Epithalon orally for one month as part of a study on intestinal enzymes. [4]
Acute rhinitis
Neurophysiological studies with intranasal administration had a completely different design. Epitalon was administered once to anaesthetised rats, and then cortical neurone activity was recorded within a short experimental window. [5]
The term „Epitalon cycle” therefore refers to a wide range of historical protocols, rather than a single, evidence-based clinical standard.
How often was Epitalon administered?
In published studies, Epitalon was administered at frequencies ranging from a single experimental dose, through daily administration during short cycles, to five doses per week and five consecutive days of administration repeated monthly. The frequency varied depending on the species and the endpoint, and no dosing frequency in humans has been established as clinically optimal. [1–5,9]
Frequency and duration should be considered separately.
The study may use a short but repeated cycle, for example five consecutive days of dosing each month.
‘Other’ may include frequent and prolonged exposure, for example, five sessions a week for several months.
In the study on SHR mice, five consecutive daily injections were administered each month. [1]
In the HER-2/neu study, five consecutive days of administration per month were also used. [9]
In the study on C3H/He mice, five injections per week were administered for 6.5 months. [3]
In contrast, an acute intranasal study in rats analysed a single administration, following which neuronal activity was immediately recorded. [5]
These schemes cannot be compared solely by the number of applications. A five-day monthly ageing protocol and a one-off intranasal electrophysiological experiment address completely different biological questions.
When were the effects of Epitalon measured in studies?
The effects of Epitalon have been measured across very different time frames — from minutes after nasal administration, through nocturnal hormone measurements and monthly biochemical endpoints, to multi-month tumour outcomes and lifelong survival. There is therefore no single evidence-based „onset of action” that would allow one to predict when a given person will feel an effect. [1,3–8]
The significance of the time to onset depends entirely on the endpoint being evaluated.
Minuty
In an in-vivo study of the rat neocortex, researchers recorded spontaneous cortical neuronal activity after acute exposure and observed changes over subsequent minutes. [5]
It was an electrophysiological endpoint, not a clinical symptom or therapeutic effect.
Evening or night
In older rhesus macaques, researchers measured evening or night-time melatonin concentrations, as this hormone is subject to a circadian rhythm. One study described significant stimulation of evening melatonin levels in ageing monkeys. [6]
Studies involving humans and monkeys have also evaluated nocturnal melatonin in the context of age-related circadian rhythm disorders. [8]
One month
In the experiment concerning intestinal enzymes in rats, the results were evaluated after one month of oral administration. [4]
A few months
The study on C3H/He mice lasted 6.5 months, and tumour development and toxicity were evaluated during this period. [3]
All my life
Some ageing studies initiated administration relatively early and continued it until the natural death of the animals, so the ultimate endpoints were lifespan and the development of spontaneous tumours. [1,2]
These differences mean that the statement „Epitalon works after X days” is not supported by the literature.
Does the duration of action vary depending on the route of administration?
Yes, the timing and study design varied depending on the route of administration, but this was due to the design of the experiments rather than evidence indicating that each route requires a specific time of day in humans. In intranasal studies, rapid neuronal responses were often analysed, oral studies assessed longer-term effects on the digestive tract, whereas injection studies frequently involved repeated protocols regarding ageing or cancer, lasting for weeks, months, or the entire lifespan of the animals.
Nasal
Epitalon administered intranasally has been studied primarily in rats.
In a 2007 neocortex experiment, intranasal administration was specifically used to analyse rapid changes in neuronal activity. [5]
The short measurement time was therefore appropriate for this specific scientific question.
However, this does not establish when nasal Epitalon should be used by humans.
By mouth
Oral administration studies have typically focused on slower-developing biological effects.
In an intestinal study on aged Wistar rats, Epithalon was administered orally for one month prior to the assessment of enzyme activity. [4]
There are no robust pharmacokinetic data in humans showing whether morning, evening, fasting or post-prandial administration significantly alters exposure to oral Epitalon.
Injections
Subcutaneous administration predominates in the classical literature on gerontology and carcinogenesis.
These studies often utilised repeated cycles lasting many months or until natural death, rather than focusing on immediate time-of-day-dependent effects. [1–3,9]
Historical injection protocols therefore provide information primarily on frequency and duration, but typically do not indicate the preferred time of administration within the circadian rhythm.
How should the evidence regarding the duration of Epitalon treatment be interpreted?
Research indicates a clear difference between the time of administration, the time of measurement and the cycle structure.
| Question about time | What do the published pieces of evidence confirm |
|---|---|
| Has it been proven that it's best to use it in the morning? | Not |
| Has it been proven that it is best to use it in the evening? | Not |
| Were measurements of the nocturnal effects carried out? | Yes, especially melatonin [6–8] |
| Have five-day cycles been studied? | Yes, in several mouse models [1,2,9] |
| Was Epitalon administered five times a week? | Yes, in some long-term animal studies [3] |
| Have monthly oral regimens been studied? | Yes, in rats [4] |
| Have the acute effects of intranasal administration been studied? | Yes, in rats [5] |
| Is there a validated cycle length for humans? | Not |
| Has the time of onset of action in humans been determined? | Not |
| Does nighttime melatonin measurement prove that taking it in the evening is best? | Not |
So the most important conclusion is:
Published Epitalon studies describe many different research regimens, but do not specify a single clinically validated time of day, cycle length, frequency, or onset of action in humans.
Frequently asked questions about the duration of Epitalon use
Should Epitalon be used in the morning or in the evening?
There are no controlled human studies demonstrating the superiority of morning or evening administration. In Epitalon studies, nocturnal melatonin levels were frequently measured because this hormone naturally follows a circadian rhythm, but the nighttime timing of the measurement does not prove that Epitalon itself should be administered in the evening.
Is Epitalon better in the evening because of melatonin?
This has not been demonstrated. Studies on primates and limited older studies involving humans have described changes in evening or night-time melatonin levels, but no study has directly compared morning versus evening administration of Epitalon to demonstrate a superior effect of evening use on melatonin, sleep, safety, or longevity. [6–8]
How long does an Epitalon cycle last?
There is no single standard cycle. Published animal studies have included five consecutive days of repeated monthly administration, schedules of five administrations per week for many months, monthly oral exposure, and long-term administration until natural death. [1–4,9]
How often was Epitalon administered in the studies?
The frequency ranged from a single acute intranasal administration to five consecutive days of administration each month or five administrations per week. The regimen depended on the species and the endpoint studied, rather than on a standardised clinical protocol. [1–5]
How quickly does Epitalon work?
No validated time to onset of action in humans has been established. Laboratory results were measured within minutes after intranasal exposure, during evening or night-time hormone measurements, after a month of oral administration, after several months, or throughout the animal's lifetime. These periods of research observation should not be interpreted as the time to onset of the treatment's action in humans.
Does nasal Epitalon work faster than injected or oral Epitalon?
Neural effects were detected in rats within minutes of intranasal administration, but this does not prove that intranasal Epitalon works more quickly or effectively clinically in humans. The different routes of administration have not been compared in controlled pharmacokinetic or efficacy studies involving humans. [5]
Limitations of evidence regarding duration of use and cycles
The biggest limitation is that most data regarding the duration of use come from animal studies rather than controlled pharmacological trials in humans.
Another limitation is the fact that individual studies were designed with different endpoints in mind. Acute neuronal activity, nocturnal melatonin, intestinal enzyme activity, tumour development and lifespan require completely different designs.
Thirdly, the literature essentially contains no direct comparisons of morning and evening administration.
Fourthly, the time of measuring results can easily be confused with the time of administration. Measuring melatonin at night does not necessarily mean the peptide was administered in the evening, and even if it was, such a design alone does not prove the superiority of that time.
Fifthly, there is a lack of robust human pharmacokinetic data. Without validated information on absorption, distribution, metabolism, elimination, and changes in exposure over time, there is no strong basis for determining the optimal chronotherapeutic administration window.
Finally, patterns repeated in older studies, such as five consecutive days a month, should be treated as specific study protocols rather than universally validated „cycles”.
Disclaimer
This material is for educational and scientific-information purposes only. It does not constitute medical advice, dosing instructions, treatment recommendations, or a recommendation for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) is not an FDA- or EMA-approved treatment for anti-aging, sleep disorders, circadian rhythm disorders, telomere modification, or longevity. No clinically validated administration schedule in humans has been established specifying morning or evening timing, duration, cycle length, or dosing frequency for these uses. The experimental schedules described above are derived mainly from animal studies and should not be translated into self-administration protocols. Individuals considering issues related to experimental peptides should consult a qualified healthcare professional and verify current regulatory information with the appropriate authorities.
References
[1] Anisimov, V. N., Khavinson, V. K., Popovich, I. G., Zabezhinski, M. A., Alimova, I. N., Rosenfeld, S. V., Zavarzina, N. Y., Semenchenko, A. V., & Yashin, A. I. (2003). Effect of Epitalon on biomarkers of ageing, life span and spontaneous tumour incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202. https://doi.org/10.1023/A:1025114230714
[2] Anisimov, V. N., Khavinson, V. K., Mikhalski, A. I., & Yashin, A. I. (2001). Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mechanisms of Ageing and Development, 122(1), 41–68. https://doi.org/10.1016/S0047-6374(00)00184-6
[3] Kossoy, G., Anisimov, V. N., Ben-Hur, H., Kossoy, N., & Zusman, I. (2006). Effect of the synthetic pineal peptide Epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo, 20(2), 253–257. https://pubmed.ncbi.nlm.nih.gov/16634527/
[4] Khavinson, V. K., Timofeeva, N. M., Malinin, V. V., Gordova, L. A., & Nikitina, A. A. (2002). Effect of Vilon and Epithalon on activity of enzymes in epithelial and subepithelial layers in small intestine of old rats. Bulletin of Experimental Biology and Medicine, 134(6), 562–564. https://pubmed.ncbi.nlm.nih.gov/12660839/
[5] Sibarov, D. A., Vol’nova, A. B., Frolov, D. S., & Nozdrachev, A. D. (2007). Effects of intranasal administration of Epitalon on neuron activity in the rat neocortex. Neuroscience and Behavioral Physiology, 37(9), 889–893. https://doi.org/10.1007/s11055-007-0095-3
[6] Khavinson, V., Goncharova, N., & Lapin, B. (2001). Synthetic tetrapeptide Epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinology Letters, 22(4), 251–254. https://pubmed.ncbi.nlm.nih.gov/11524632/
[7] Goncharova, N. D., Vengerin, A. A., Khavinson, V. K., & Lapin, B. A. (2005). Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Experimental Gerontology, 40(1–2), 51–57. https://doi.org/10.1016/j.exger.2004.10.004
[8] Korkushko, O. V., Lapin, B. A., Goncharova, N. D., Khavinson, V. K., Shatilo, V. B., Vengerin, A. A., Antoniuk-Shcheglova, I. A., & Magdich, L. V. (2007). Normalising effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Advances in Gerontology, 20(1), 74–85. https://pubmed.ncbi.nlm.nih.gov/17969590/
[9] Anisimov, V. N., Khavinson, V. K., Alimova, I. N., Provinciali, M., Mancini, R., & Franceschi, C. (2002). Epithalon inhibits tumour growth and expression of HER-2/neu oncogene in breast tumours in transgenic mice characterised by accelerated ageing. Bulletin of Experimental Biology and Medicine, 133(2), 167–170. https://doi.org/10.1023/A:1015555023692